Data Sheet 2_Comparative efficacy, safety, and functional recovery of neonatal fc receptor inhibitors and conventional immunotherapies for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and network meta-analysis.zip

Treatments were ranked using P-scores, and certainty of evidence was summarized using CINeMA/GRADE domains.</p>Findings<p>Eighteen RCTs (n=2,184) were included. In the primary efficacy network (I2 = 0.37%), PLEX (OR 33.60, 95% CI 3.15–358.90; P-score 0.9415) and corticosteroids (OR 15.44, 95% CI 3.53–67.47; P-score 0.9056) demonstrated the highest probability of achieving clinical response. Efgartigimod alfa showed significant clinical response (OR 3.14, 95% CI 1.34–7.33) and ranked highest for grip-strength change (SMD 0.67, 95% CI 0.09–1.24; P-score 0.8847), although this analysis was based on five studies and should be interpreted as a distal motor outcome rather than a comprehensive functional endpoint.

For secondary outcomes, FcRn inhibitors had SAE estimates comparable to placebo (efgartigimod OR 1.00, 95% CI 0.31–3.20; rozanolixizumab OR 0.94, 95% CI 0.05–16.37), and rozanolixizumab ranked highest for DCAE/acceptability (P-score 0.7896). Heterogeneity was low to modest across secondary networks (SAEs I2 = 12.40%; DCAE I2 = 0.00%; grip strength I2 = 24.10%).</p>Interpretation<p>PLEX and corticosteroids showed the strongest relative effects for short-term clinical response, whereas efgartigimod alfa showed a significant treatment effect and the highest ranking for grip-strength change among studies reporting this distal motor measure.

IVIg remains a broadly supported comparator across induction and maintenance settings. These findings should inform, but not replace, individualized clinical decision-making because patient-level treatment-effect modification, biomarker status, prior treatment response, and long-term neurophysiological outcomes were not directly evaluated.</p>